...
首页> 外文期刊>Pharmacogenomics >Influence of beta-adrenergic receptor genotypes on heart rate response to metoprolol treatment
【24h】

Influence of beta-adrenergic receptor genotypes on heart rate response to metoprolol treatment

机译:β-肾上腺素能受体基因型对美托洛尔治疗对心率反应的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Among the various uses of beta-blockers is reduction/stabilization of the heart rate (HR) of heart disease patients in order to obtain images of sufficient quality upon noninvasive coronary computed tomo-graphic angiography (CCTA) [1]. A steady HR of less than 60 bpm is recommended for this type of diagnostic imaging [2]. The most common P-adrenergic receptor (AR) antagonist used for this indication is metoprolol, a beta_1-AR subtype-selective antagonist with several documented benefits in human heart failure [3]. Despite optimal dosing, however, metoprolol is often ineffective at lowering HR, and genetic variability in human betaAR genes has been implicated in this heterogeneity of patient response to its administration [4]. However, the effect, if any, of betaAR genetic variations on metoprolol HR response in individuals immediately prior to undergoing CCTA has never been studied.
机译:β受体阻滞剂的各种用途包括降低/稳定心脏病患者的心率(HR),以便在无创冠状动脉计算机断层血管造影术(CCTA)上获得足够质量的图像[1]。对于这种类型的诊断成像,建议将HR稳定在60 bpm以下[2]。用于该适应症的最常见的P-肾上腺素能受体(AR)拮抗剂是美托洛尔,它是一种对人心力衰竭有多项已证实益处的β_1-AR亚型选择性拮抗剂。尽管有最佳剂量,但是美托洛尔在降低HR方面常常无效,而且人类betaAR基因的遗传变异性也与患者对其给药反应的异质性有关[4]。但是,从未研究过βAR基因变异对CCTA临临个体中美托洛尔HR反应的影响(如果有的话)。

著录项

  • 来源
    《Pharmacogenomics》 |2013年第13期|共2页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号